In this interview, we discuss a study of sex differences in the tolerability of anti–programmed death 1 immunotherapy among patients with metastatic melanoma.
Narjust Duma, MD
Advertisement
Articles by Narjust Duma, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
5